Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate

Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Clin Oncol
Hlavní autoři: Yasui, Masato, Hasegawa, Yoriko, Kawahara, Takashi, Kumano, Yohei, Miyoshi, Yasuhide, Matsubara, Nobuaki, Uemura, Hiroji
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2018
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838297/
https://ncbi.nlm.nih.gov/pubmed/29541468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1573
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky